GU Cancers 2021 | STRONG: fixed-dose durvalumab for UTC

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, shares results from a final analysis of the Phase IIIb STRONG trial (NCT03084471) evaluating fixed-dose durvalumab monotherapy for patients with urinary tract carcinoma (UTC). The STRONG trial allowed for the participation of patients with nonurothelial cancer and patients who had received chemotherapy that was not platinum based. A total of 867 patients were treated with durvalumab. The trial found the efficacy and safety profile was similar to that shown in previous studies with an objective response rate (ORR) of 17.7% and complete responses in 5.1% of patients. This interview took place during the 2021 Genitourinary Cancers Symposium.